Hyperbaric Oxygen Therapy in the Management of Refractory Perianal Crohn's Disease | Canada Hyperbarics Skip to main content
Study J Clin Med 2025

Hyperbaric Oxygen Therapy in the Management of Refractory Perianal Crohn's Disease

Hajjar R, Bews K, Alaoui A, Khan S, Gleason L, Sanchez E, et al. — J Clin Med, 2025

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Researchers at the Mayo Clinic reviewed the medical records of six patients with perianal Crohn's disease who received hyperbaric oxygen therapy (HBOT) between 2014 and 2023.

What They Found

Six patients, aged 19 to 60, with perianal Crohn's disease received between 10 and 40 sessions of HBOT. Four of these patients (67%) reported an improvement in their symptoms. However, only one patient showed objective improvement on physical examination or imaging assessment.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

This study was limited by its very small sample size of only six patients and its retrospective design, which can introduce bias.

Was this summary helpful?

Study Details

Study Type Study
Category Uncategorised
Source Pubmed
PubMed ID 41095923
Year Published 2025
Journal J Clin Med

Cite This Study

Share

Find a Canadian Clinic Treating Uncategorised

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.